A Multiplex Cancer/Testis Antigen-Based Biomarker Panel to Predict the Aggressive Phenotype of Prostate Cancer
Abstract
The Cancer/Testis Antigens (CTAs) are a unique group of proteins that are normally confined to germ cells but aberrantly expressed in several types of cancers. Several studies have shown that their expression patterns are frequently associated with higher grade lesions and advanced disease with a poorer outcome. The central hypothesis of this grant application is that a CTA-based biomarker can be used to discern PCa patients with aggressive disease (high likely hood of recurrence following RP, presentation of advanced disease and/or cancer specific mortality) and hence would need definitive treatment from those in whom it is less likely to recur (less likely to recur post RP or advance) and would therefore, not require immediate intervention. In the first year of this grant our goal was to accomplish Specific Aim namely, identify candidate CTAs that are differentially expressed in clinically organ-confined PCa and metastatic PCa tissues using the NanoString technology. The results indicate that NanoString nCounter analysis is an appropriate platform to analyze CTAs expression in samples from PCa patients and CTAs can be used to differentiate metastatic PCa from localized PCa.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2013
- Accession Number
- ADA590492
Entities
People
- Prakash Kulkarni
Organizations
- Johns Hopkins University